Key Points

  • The composite of recurrent VTE and major bleeding was nonsignificantly lower for DOACs than for LMWHs.

  • DOACs should be used with caution in patients at high risk for bleeding.

Abstract

Direct oral anticoagulants (DOACs) are an emerging treatment option for patients with cancer and acute venous thromboembolism (VTE), but studies have reported inconsistent results. This systematic review and meta-analysis compared the efficacy and safety of DOACs and low-molecular-weight heparins (LMWHs) in these patients. MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, and conference proceedings were searched to identify relevant randomized controlled trials. Additional data were obtained from the original authors to homogenize definitions for all study outcomes. The primary efficacy and safety outcomes were recurrent VTE and major bleeding, respectively. Other outcomes included the composite of recurrent VTE and major bleeding, clinically relevant nonmajor bleeding (CRNMB), and all-cause mortality. Summary relative risks (RRs) were calculated in a random effects meta-analysis. In the primary analysis comprising 2607 patients, the risk of recurrent VTE was nonsignificantly lower with DOACs than with LMWHs (RR, 0.68; 95% CI, 0.39-1.17). Conversely, the risks of major bleeding (RR, 1.36; 95% CI, 0.55-3.35) and CRNMB (RR, 1.63; 95% CI, 0.73-3.64) were nonsignificantly higher. The risk of the composite of recurrent VTE or major bleeding was nonsignificantly lower with DOACs than with LMWHs (RR, 0.86; 95% CI, 0.60-1.23). Mortality was comparable in both groups (RR, 0.96; 95% CI, 0.68-1.36). Findings were consistent during the on-treatment period and in those with incidental VTE. In conclusion, DOACs are an effective treatment option for patients with cancer and acute VTE, although caution is needed in patients at high risk of bleeding.

REFERENCES

REFERENCES
1.
Prandoni
P
,
Lensing
AW
,
Piccioli
A
, et al
.
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis
.
Blood
.
2002
;
100
(
10
):
3484
-
3488
.
2.
Lee
AYY
,
Kamphuisen
PW
,
Meyer
G
, et al;
CATCH Investigators
.
Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial
.
JAMA
.
2015
;
314
(
7
):
677
-
686
.
3.
Lee
AYY
,
Levine
MN
,
Baker
RI
, et al;
Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators
.
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer
.
N Engl J Med
.
2003
;
349
(
2
):
146
-
153
.
4.
Khorana
AA
,
Yannicelli
D
,
McCrae
KR
, et al
.
Evaluation of US prescription patterns: are treatment guidelines for cancer-associated venous thromboembolism being followed?
Thromb Res
.
2016
;
145
:
51
-
53
.
5.
Kahn
SR
,
Springmann
V
,
Schulman
S
, et al
.
Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting. The Recovery Study
.
Thromb Haemost
.
2012
;
108
(
3
):
493
-
498
.
6.
Seaman
S
,
Nelson
A
,
Noble
S
.
Cancer-associated thrombosis, low-molecular-weight heparin, and the patient experience: a qualitative study
.
Patient Prefer Adherence
.
2014
;
8
:
453
-
461
.
7.
Kearon
C
,
Akl
EA
,
Ornelas
J
, et al
.
Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report [published correction appears in Chest. 2016;150(4):988]
.
Chest
.
2016
;
149
(
2
):
315
-
352
.
8.
Raskob
GE
,
van Es
N
,
Verhamme
P
, et al
.
Edoxaban for the treatment of cancer-associated venous thromboembolism
.
N Engl J Med
.
2018
;
378
(
7
):
615
-
624
.
9.
Young
AM
,
Marshall
A
,
Thirlwall
J
, et al
.
Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)
.
J Clin Oncol
.
2018
;
36
(
20
):
2017
-
2023
.
10.
McBane
RDII
,
Wysokinski
WE
,
Le‐Rademacher
JG
, et al
.
Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial
.
J Thromb Haemost
.
2020
;
18
(
2
):
411
-
421
.
11.
Agnelli
G
,
Becattini
C
,
Meyer
G
, et al
.
Apixaban for the treatment of venous thromboembolism associated with cancer
.
N Engl J Med
.
2020
;
382
(
17
):
1599
-
1607
.
12.
Moher
D
,
Liberati
A
,
Tetzlaff
J
,
Altman
DG
;
PRISMA Group
.
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
.
PLoS Med
.
2009
;
6
(
7
):
e1000097
.
13.
Sterne
JAC
,
Savović
J
,
Page
MJ
, et al
.
RoB 2: a revised tool for assessing risk of bias in randomised trials
.
BMJ
.
2019
;
366
:
l4898
.
14.
Schulman
S
,
Kearon
C
;
Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis
.
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients
.
J Thromb Haemost
.
2005
;
3
(
4
):
692
-
694
.
15.
Deeks
JJ
.
Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes
.
Stat Med
.
2002
;
21
(
11
):
1575
-
1600
.
16.
Schünemann
HJ
,
Higgins
JP
,
Vist
GE
, et al
. Completing “Summary of findings” tables and grading the certainty of the evidence. In:
Higgins
JPT
,
Thomas
J
,
Chandler
J
et al
, eds.
Cochrane Handbook for Systematic Reviews of Interventions
. 2nd ed.
Hoboken, NJ
:
John Wiley & Sons Ltd.
;
2019
;
375
-
402
.
17.
Cornell
JE
,
Mulrow
CD
,
Localio
R
, et al
.
Random-effects meta-analysis of inconsistent effects: a time for change
.
Ann Intern Med
.
2014
;
160
(
4
):
267
-
270
.
18.
Knapp
G
,
Hartung
J
.
Improved tests for a random effects meta-regression with a single covariate
.
Stat Med
.
2003
;
22
(
17
):
2693
-
2710
.
19.
Mulder
FI
,
Di Nisio
M
,
Ay
C
, et al
.
Clinical implications of incidental venous thromboembolism in cancer patients
.
Eur Respir J
.
2020
;
55
(
2
):
1901697
.
20.
Key
NS
,
Khorana
AA
,
Kuderer
NM
, et al
.
Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline Update
.
J Clin Oncol
.
2020
;
38
(
5
):
496
-
520
.
21.
Streiff
MB
,
Holmstrom
B
,
Angelini
D
, et al
.
NCCN guidelines insights: cancer-associated venous thromboembolic disease, version 2.2018
.
J Natl Compr Canc Netw
.
2018
;
16
(
11
):
1289
-
1303
.
22.
Mandalà
M
,
Falanga
A
,
Roila
F
;
ESMO Guidelines Working Group
.
Management of venous thromboembolism (VTE) in cancer patients: ESMO clinical practice guidelines
.
Ann Oncol
.
2011
;
22
(
suppl 6
):
vi85
-
vi92
.
23.
Mulder
FI
,
van Es
N
,
Kraaijpoel
N
, et al
.
Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study
.
Thromb Res
.
2020
;
185
(
185
):
13
-
19
.
24.
Kraaijpoel
N
,
Di Nisio
M
,
Mulder
FI
, et al
.
Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer Study
.
Thromb Haemost
.
2018
;
118
(
8
):
1439
-
1449
.
25.
Fralick
M
,
Colacci
M
,
Schneeweiss
S
,
Huybrechts
KF
,
Lin
KJ
,
Gagne
JJ
.
Effectiveness and safety of apixaban compared with rivaroxaban for patients with atrial fibrillation in routine practice: a cohort study
.
Ann Intern Med
.
2020
;
172
(
7
):
463
-
473
.
26.
Noseworthy
PA
,
Yao
X
,
Abraham
NS
,
Sangaralingham
LR
,
McBane
RD
,
Shah
ND
.
Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation
.
Chest
.
2016
;
150
(
6
):
1302
-
1312
.
27.
Lip
GYH
,
Keshishian
A
,
Li
X
, et al
.
Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients
.
Stroke
.
2018
;
49
(
12
):
2933
-
2944
.
28.
Kraaijpoel
N
,
Tritschler
T
,
Guillo
E
,
Girard
P
,
Le Gal
G
.
Definitions, adjudication, and reporting of pulmonary embolism-related death in clinical studies: a systematic review
.
J Thromb Haemost
.
2019
;
17
(
10
):
1590
-
1607
.
29.
Steffel
J
,
Verhamme
P
,
Potpara
TS
, et al;
ESC Scientific Document Group
.
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
.
Eur Heart J
.
2018
;
39
(
16
):
1330
-
1393
.
30.
Guolo
A
,
Varin
C
.
Random-effects meta-analysis: the number of studies matters
.
Stat Methods Med Res
.
2017
;
26
(
3
):
1500
-
1518
.
You do not currently have access to this content.